NAD+ IV therapy is a medical treatment that involves administering NAD+ directly into the bloodstream through...
The use of KCF-18, a peptide originating from cytokine receptors, as a therapeutic approach for anti-inflammatory purposes through binding to proinflammatory cytokines.
The use of peptides derived from cytokine receptors as a therapeutic strategy for anti-inflammation has been investigated. These peptides are designed to specifically bind proinflammatory cytokines, providing a potential means of regulating immune responses. Through this mechanism, the peptides may serve as a valuable tool in the development of novel immunomodulatory agents.